Preoperative Transcatheter Selective Arterial Chemoembolization in Treatment of Unresectable Hepatoblastoma in Infants and Children
- First Affiliated Hospital, Sun Yat-sen University, Department of Interventional Radiology (China)
The purpose of this study was to evaluate the clinical feasibility and efficacy of transcatheter selective arterial chemoembolization (TACE) for unresectable hepatoblastoma in infants and children. The study was performed with the approval of our institutional review board. Sixteen patients (13 boys, 3 girls) with unresectable hepatoblastoma were treated one to three times with preoperative TACE in an effort to improve the surgical and clinical outcome. Their ages ranged from 50 days to 60 months, with a mean age of 20.4 months. All cases were pathologically proved hepatoblastoma by fine-needle biopsy. After an intra-arterial catheter was selectively inserted into the main feeding artery of the tumor, cycles of cisplatin (40 to 50 mg/m{sup 2}) and adriamycin (20 to 30 mg/m{sup 2}) mixed with lipiodol were given, followed by gelatin foam particles or stainless-steel coils. Tumor response was evaluated according to tumor shrinkage, {alpha}-fetoprotein (AFP) levels, and pathological findings. TACE procedure was performed one to three times, depending on the patient's response. Surgical resection was carried out when the tumor volume appeared sufficiently reduced to allow safe resection by either lobectomy or extended lobectomy. A marked reduction in tumor size associated with decreased AFP level occurred after treatment. According to paired-samples test, tumor shrinkage ranged from 19.0% to 82.0%, with a mean value of 59.2%. AFP levels decreased 99.0% to 29.0% from initial levels, with a mean decrease of 60.0%. TACE allowed subsequent complete surgical resection in 13 cases and the other 3 cases underwent partial resection. One patient underwent successful orthotopic liver transplantation after receiving TACE therapy. Pathological examination showed that the mean percentage of necrotic area in the surgical specimens was 87%. Overall survival rate at 1, 3, and 5 years was 87.5%, 68.7%, and 50%, respectively. Correspondingly, event-free survival rate was 75%, 62.5%, and 43.7%, respectively. In addition, there was no marked chemotherapeutic agent-induced toxicity noted during the observation period. We conclude that TACE is feasible, well tolerated, and effective in inducing surgical resectability of hepatoblastoma in pediatric patients, which has become an independent palliative or curative therapeutic option, especially for patients without distant metastasis.
- OSTI ID:
- 21426339
- Journal Information:
- Cardiovascular and Interventional Radiology, Vol. 31, Issue 6; Other Information: DOI: 10.1007/s00270-008-9373-x; Copyright (c) 2008 Springer Science+Business Media, LLC; ISSN 0174-1551
- Country of Publication:
- United States
- Language:
- English
Similar Records
Radioimmunotherapy for hepatocellular carcinoma (HCC) using /sup 131/I-anti HCC isoferritin IgG: preliminary results of experimental and clinical studies
An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone
Related Subjects
ARTERIES
DOXORUBICIN
GELATIN
INFANTS
LIPIODOL
LIVER
NEOPLASMS
STAINLESS STEELS
SURGERY
AGE GROUPS
ALLOYS
ANIMALS
ANTIBIOTICS
ANTI-INFECTIVE AGENTS
ANTINEOPLASTIC DRUGS
BLOOD VESSELS
BODY
CARBON ADDITIONS
CARDIOVASCULAR SYSTEM
CHILDREN
COLLOIDS
CONTRAST MEDIA
DIGESTIVE SYSTEM
DISEASES
DISPERSIONS
DRUGS
GLANDS
HIGH ALLOY STEELS
IRON ALLOYS
IRON BASE ALLOYS
MAMMALS
MAN
MEDICINE
OILS
ORGANIC COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC IODINE COMPOUNDS
ORGANS
OTHER ORGANIC COMPOUNDS
PRIMATES
PROTEINS
STEELS
TRANSITION ELEMENT ALLOYS
VERTEBRATES